MEDO Technologies, Inc.

What they do

Byrn Inc., formerly Quture International, Inc., was formed in April 2011 as a healthcare knowledge solution company and later described itself as a holding company for digital, data-led retail supply chain solutions. The 10-K states the company is currently a dormant shell company, and the 10-Q states it has no operations from a continuing business other than expenditures related to running the company. Its sole activity is SEC reporting and evaluating a potential new business plan.

Revenue drivers

• No revenue-generating business — The 10-Q states the company has no revenue from operations as of the report date; no product or segment revenue is reported.

Recent performance

Annual net losses were $21,221 in 2023, $44,987 in 2024, and $40,025 in 2025, with net income of negative $87.7 million in 2021 and negative $4,752 in 2022. Operating cash flow was negative $15,677 in 2023, negative $46,075 in 2024, and negative $45,800 in 2025. At June 30, 2026, total assets were $1,909, total liabilities were $206,170, shareholders' equity was negative $204,260, and cash and equivalents were $0.00. Historical revenue of $19,900 in 2011 and $40,900 in 2012 is not comparable to the current dormant shell.

Strategy

On April 24, 2026, MEDO Healthcare LLC, an Iowa limited liability company, purchased 10 million shares of Series A Preferred Stock from Custodian Ventures LLC for $175,000 in cash. The principals of MEDO Healthcare plan to rename the company MEDO Technologies, Inc., where MEDO stands for Machine Enhanced Diagnostic Optimization. The stated plan is to acquire pharmaceuticals distributors with nationwide scope and introduce proprietary AI-based technology to specialty retail, specialty mail-order, and SNF/ALF institutional verticals. Management states it may need capital as a condition of closing acquisitions and may issue a controlling block of securities to target shareholders.

Risks

• No operating business or revenue — The 10-Q states the company has no operations from a continuing business other than running the company and no revenue from operations.
• Insufficient working capital — Management states it does not have sufficient working capital to fund operations over the next 12 months and may be unable to raise capital on acceptable terms.
• Acquisition execution uncertainty — The plan to acquire pharmaceuticals distributors and apply AI technology depends on financing and unidentified targets, with no assurance of success.
• Dilution from future financings — The 10-Q warns that additional equity or convertible debt issuances will dilute current shareholders and may carry senior rights or preferences.

Outlook

Management expects to incur operating losses over the next 12 months, principally costs related to SEC filing obligations. The company intends to pursue acquisitions of pharmaceuticals distributors and to implement an AI-based technology plan under the MEDO Technologies name. Management cautions that it cannot be certain how much capital it needs to raise or what securities it will issue, and that financing may not be available on acceptable terms or at all.